STAT
SEPTEMBER 30, 2024
Health care stocks stumbled compared with the rest of the market in 2023. Companies missed their profit targets. Some CEOs even lost their bonuses. But the biggest names in health care still made $3.5 billion combined last year, compared with $4 billion in 2022. The average chief executive brought home $11 million, while the median was $4.1 million.
PharmaVoice
SEPTEMBER 30, 2024
The company’s allogeneic therapy was OK’d in the EU and could become the first of its kind approved by the FDA in January — while eyeing the next frontier.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
SEPTEMBER 30, 2024
When I was a medical student in the 1980s, the school hired “pelvic instructors” who taught us how to do exams in a painless and respectful way. They even allowed us to perform practice examinations on them. But at the same time, senior doctors urged me to perform pelvic exams on anesthetized women about to get surgery — women who never gave consent.
ALiEM - Pharm Pearls
SEPTEMBER 30, 2024
A 23-year-old healthy male presented to the emergency department with left eye pain, soreness, and blurry vision after being hit in the left eye with a Nerf gun bullet two days prior. He had no prior ophthalmologic history and does not wear corrective lenses. Physical Exam Left eye : Visual acuity 20/30. Intraocular Pressure 17. Pupil 3mm, irregular, minimally reactive.
Speaker: Jennifer Hill
Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.
STAT
SEPTEMBER 30, 2024
Prime Medicine, founded with gene-editing tech from the lab of star Harvard biochemist David Liu and backed by blue chip investors, made little secret of its ambition. It laid out plans to use its new gene-editing technology across 18 different diseases, listing conditions as disparate as ALS, congenital blindness, and muscular dystrophy.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
STAT
SEPTEMBER 30, 2024
DCVC Bio, a Silicon Valley area investment firm launched six years ago by a group of tech, bio, and agriculture investors, has raised a new $400 million fund, it told STAT exclusively. This is the third fund DCVC Bio has raised. It came in ahead of the original $350 million goal, according to executives. The announcement makes DCVC Bio one of a select number of biotech VCs to raise new pools of capital this year.
The Pharmacist
SEPTEMBER 30, 2024
Some pharmacists are being expected to fulfil flu vaccination bookings as frequently as every five minutes, the Pharmacists' Defence Association (PDA) has said. It raised concerns that expectations around flu vaccination delivery are affecting workload, stress and the delivery of other pharmacy services. The association told The Pharmacist that it has received an increase in calls from […] The post Pharmacists concerned about flu vaccination workload, says PDA appeared first on The Pharmac
STAT
SEPTEMBER 30, 2024
At last count, the Food and Drug Administration has authorized 950 medical devices that use artificial intelligence and machine learning. But far fewer have made a significant impact on patient care in the United States. For medical AI developers like James Zou, that’s a problem. The Stanford professor is invested in getting effective medical machine learning — including some of his own, FDA-cleared algorithms — adopted by health systems.
The Pharmacist
SEPTEMBER 30, 2024
Changes to hub and spoke regulation will not come into effect on 1 January 2025, as was previously intended, according to Community Pharmacy England (CPE). This is because the government needs time to brief new ministers before the proposed changes can be implemented, CPE has suggested. The negotiator said it did not have further clarity […] The post Hub and spoke changes 'delayed beyond 1 January' appeared first on The Pharmacist.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
STAT
SEPTEMBER 30, 2024
LONDON — Roche executives on Monday argued that their experimental obesity medications would prove to have advantages over their rivals’ products — and that the huge demand for effective weight loss drugs means there is room for another company in the field. “We wouldn’t have moved forward with these assets if we didn’t feel they were differentiated,” including in their molecular makeup and how they could be used in combination with other treatmen
BioPharma Dive
SEPTEMBER 30, 2024
The Swiss pharma is paying Regor Therapeutics $850 million to buy a pair of prospects it sees as potential successors to blockbuster medicines from Pfizer and Eli Lilly.
STAT
SEPTEMBER 30, 2024
Dear Reader, STAT is on fire! Not literally, of course.
pharmaphorum
SEPTEMBER 30, 2024
Chiesi Biotech Center of Excellence opens to strengthen R&D in Italy Nicole.
Advertisement
Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.
STAT
SEPTEMBER 30, 2024
This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news delivered straight to your inbox. Hello! Today, we talk about how much dang money some CEOs still make, despite the slowdown in the biotech industry. We also see Dupixent approved for a huge new indication, and more.
pharmaphorum
SEPTEMBER 30, 2024
Genentech buys Regor's next-gen CDK inhibitors for $850M Jonah.
STAT
SEPTEMBER 30, 2024
How much health care’s bigwigs are making Mike Reddy for STAT Health care stocks lagged behind the broader market in 2023, and that was reflected in many CEO pay packages. My colleagues and I completed our annual tradition of analyzing CEO compensation. For 2023, we input data for 313 health care CEOs and found they made $3.5 billion combined last year , compared with $4 billion in 2022.
Pharmaceutical Commerce
SEPTEMBER 30, 2024
Why looming benefit changes—and the resulting unintended consequences—are a concern for patients.
Speaker: Joe Sharpe and James Carlson
Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.
STAT
SEPTEMBER 30, 2024
Good morning! What would you buy if you earned $305 million in one year? Maybe I’d have a different color KitchenAid mixer for every season. Bird flu: More questions than answers as more health worker sickness is revealed An investigation into a still unexplained human case of bird flu in Missouri has turned up four more health care workers who developed mild respiratory symptoms after caring for the patient, the CDC reported on Friday.
pharmaphorum
SEPTEMBER 30, 2024
Find out how AI can help prevent burnout and optimise pharmacist time in the pharmacy setting. Learn how technology can streamline processes and improve efficiency in this crucial healthcare profession.
STAT
SEPTEMBER 30, 2024
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of deadlines, online meetings and phone calls has predictably returned. But what can you do? The world, such as it is, continues to spin. So time to give it a nudge in a better direction by brewing cups of stimulation.
Express Pharma
SEPTEMBER 30, 2024
Alembic Pharmaceuticals announces that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Oral Solid Formulation Facility (F-I) located in Panelav. The inspection, which took place from July 17, 2024, to July 26, 2024, has been successfully concluded. With this, all of the company’s USFDA-approved facilities now have EIRs in place.
Advertisement
Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.
Pharmaceutical Technology
SEPTEMBER 30, 2024
The first needle-free epinephrine nasal spray, Neffy by ARS Pharmaceuticals, represents a significant breakthrough in emergency treatment for type I allergic reactions.
Express Pharma
SEPTEMBER 30, 2024
Venus Remedies has secured marketing authorisations for two key cancer drugs. The approvals include bortezomib in the Philippines and carboplatin in Morocco. The Philippine market, the second largest in the ASEAN region, is expected to grow from $400 million in 2022 to $790 million by 2030. The authorisation of bortezomib aims to enhance the company’s ability to deliver advanced cancer solutions in Southeast Asia.
Drug Patent Watch
SEPTEMBER 30, 2024
Patent expirations have a significant impact on the pharmaceutical industry, particularly on the generic drug market. When a drug’s patent expires, other manufacturers can produce and market generic versions of the drug, leading to increased competition and lower prices.
Express Pharma
SEPTEMBER 30, 2024
Healthcare professionals widely recognise the microbiome’s vital contributions to digestion, immune function, and overall well-being. The majority of surveyed respondents view a balanced microbiome as essential to sustain health and prevent various diseases, underscoring its crucial role of in maintaining human health, according to a recent poll conducted by GlobalData.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharmaceutical Commerce
SEPTEMBER 30, 2024
Why this trend is occurring and ways that drugmakers are pivoting in order to remedy the situation.
Express Pharma
SEPTEMBER 30, 2024
Piramal Pharma Solutions (PPS), a Contract Development and Manufacturing Organisation (CDMO) under Piramal Pharma, has announced an $80 million investment plan to expand its Lexington, Kentucky facility. The site specialises in sterile compounding, liquid filling, and lyophilisation for sterile injectable drug products. The investment will enhance the facility’s capacity and capabilities, aligning with the growing market demand for these services.
pharmaphorum
SEPTEMBER 30, 2024
Discover the latest mergers, acquisitions, and partnerships in July 2024 involving Glycotope, Anacura, and JenaValve Technology in this insightful article. Stay informed on the closed and collaborative developments in these companies.
Expert insights. Personalized for you.
362 
Let's personalize your content